Novartis AG (SWX: NOVN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 181.91B |
| Revenue (ttm) | 42.18B |
| Net Income (ttm) | 14.87B |
| Shares Out | 2.00B |
| EPS (ttm) | 7.25 |
| PE Ratio | 18.80 |
| Forward PE | 12.33 |
| Dividend | 3.30 (3.63%) |
| Ex-Dividend Date | n/a |
| Volume | 369,362 |
| Open | 91.68 |
| Previous Close | 90.99 |
| Day's Range | 90.99 - 91.68 |
| 52-Week Range | 83.63 - 102.72 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2024 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and ... [Read more]
Financial Performance
In 2023, Novartis AG's revenue was $46.66 billion, an increase of 7.36% compared to the previous year's $43.46 billion. Earnings were $14.85 billion, an increase of 113.52%.
Financial numbers in USD Financial StatementsNews
Novartis: launch of Morphosys drug by could be 2027 or later
Novartis' CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safet...
Novartis (NVS) Boosts Mid-Term Sales Forecast Amid Strong Drug Performance
Novartis (NVS) Boosts Mid-Term Sales Forecast Amid Strong Drug Performance
Novartis Lifts Sales Outlook on Key Drugs, Pipeline Portfolio
The pharma company raised its guidance on revenue growth from its key treatments and expected drug launches, and now anticipates annual currency-adjusted sales to grow by 6% through 2028.
Novartis raises annual sales guidance until 2028
Novartis on Thursday raised its medium-term sales guidance, predicting 6% annual growth through 2028, driven by strong momentum of launched drugs and the prospect of upcoming market introductions.
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029 Strong momentum in the business with 8 in-market brands with USD 3bn+ to USD 8bn+ pe...
Novartis ranks first in 2024 Access to Medicine Index
Basel, November 19, 2024 – Novartis has ranked first in the 2024 Access to Medicine Index (ATMI) report published today, highlighting the company's leadership in improving access to medicines around t...
Novartis, Ratio to collaborate on SSTR2 radiotherapeutic for cancer
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
Ratio to receive upfront, and potential milestones and tiered royalty payments BOSTON , Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative tec...
PPI, Novartis hold media workshop to enhance health literacy in managing cholesterol, promote heart health
The Philippine Press Institute (PPI) held a health reporting workshop to help local journalists gain a deeper understanding of low-density lipoprotein cholesterol (LDL-C or “bad cholesterol”) manageme...
Schrödinger gains on Novartis deal despite Q3 miss
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
Schrodinger, Inc. (NASDAQ: SDGR) shares are trading higher on Tuesday. The company disclosed a research collaboration and license agreement with Novartis AG (NYSE: NVS) to advance multiple developme...
Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer
SOUTH SAN FRANCISCO, Calif. & BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cellares, the world's first Integrated Development and Manufacturing Organization (IDMO), and a leader in automated cell therapy manuf...
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced a multi-target collaboration and expanded software licensing agreement with Novartis.
Genmab Announces Financial Results for the First Nine Months of 2024
November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY ® (...
Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper
Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant having nothing to fear from ...
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
On Tuesday, Novartis AG (NYSE: NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion . Guidance: Novartis also raised its 20...
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
On Tuesday, Novartis AG NVS reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion.
Novartis: It's Not Too Late To Buy This Dividend Stock Now
Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock and why it is a Buy.
Focus remains on R&D to drive growth of blockbuster drugs, says Novartis CEO
Vas Narasimhan, CEO at Novartis, discusses third-quarter results, and explains the strategy behind development of the company's most in-demand treatments.
Focus remains on R&D to drive growth of blockbuster drugs, says Novartis CEO
Vas Narasimhan, CEO at Novartis, discusses third-quarter results, and explains the strategy behind development of the company's most in-demand treatments.
Novartis: Strong Financials, But Market Skepticism Persists Amid Pipeline Concerns
Novartis reported a strong Q3 2024 with 9% YoY sales growth, largely driven by its top four drugs. Pluvicto and Leqvio saw significant growth but investor disappointment stemmed from a revenue adjustm...
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial ...
Novartis AG (NVS) Q3 2024 Earnings Call Transcript
Novartis AG (NYSE:NVS) Q3 2024 Earnings Conference Call October 29, 2024 9:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirs...
Novartis CEO on the impact of the U.S. election for pharma
Novartis CEO Vas Narasimhan talks to CNBC about the company's latest results and the potential impact of the U.S. election on the business.